At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 388 enrolled
Drug / intervention
Lurasidone tablets +1 moredrug
Likely dose
Risperidone tablets 6mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone
In Brief
A Phase 3 clinical trial evaluating Lurasidone tablets and Risperidone tablets for Schizophrenia. Completed, enrolled 388 participants across 15 sites.
Detailed Summary
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and to compare with risperidone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionApr 2015
Study CompletionNov 2015
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartDec 1, 2013
Primary CompletionApr 1, 2015
Study CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.6 years ago
Interventions
Lurasidone tabletsdrug
Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
Risperidone tabletsdrug
Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)